{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-028289","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.111857+00:00","generated_at":"2026-06-12T00:29:15.197716+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cumberland Pharma Q2 revenue $10.9M (+6% YoY); net income $0.9M","bullets":["Q2 net revenue $10.9M (+6% vs prior year, +18% sequential); YTD revenue $20.1M.","Q2 net income $0.9M ($0.06/diluted share); YTD net income $1.1M ($0.07/share).","Adjusted Q2 earnings $2.3M ($0.16/share); YTD adjusted $4.0M ($0.27/share).","FDA approved Caldolor for infants (3-6 months) in May; study results published June.","Received $2.8M in FDA barrier-to-innovation fee waivers in June 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-028289","json":"https://secwatch.observer/filing/0001628280-23-028289.json","markdown":"https://secwatch.observer/filing/0001628280-23-028289.md","text":"https://secwatch.observer/filing/0001628280-23-028289.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023028289/0001628280-23-028289-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023028289/cpix-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T00:29:15.197716+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}